 Viatris Inc NASDAQ: VTRS, previously known as Mylan, has agreed to pay 264 million to resolve a class-action lawsuit alleging it engaged in a scheme to delay generic competition to its EpiPen allergy treatment. The proposed settlement would resolve litigation following public. 